| Schedule of Segment Loss Including Significant Segment Expenses |
The table below is a summary of the segment loss, including significant segment expenses (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
Program expenses |
|
|
|
|
|
|
|
|
|
|
|
|
Navacaprant (NMRA-140) program |
|
$ |
(22,257 |
) |
|
$ |
(25,552 |
) |
|
$ |
(46,750 |
) |
|
$ |
(49,871 |
) |
M4 PAM programs |
|
|
(2,370 |
) |
|
|
(1,278 |
) |
|
|
(5,252 |
) |
|
|
(4,802 |
) |
NMRA-511 program |
|
|
(2,257 |
) |
|
|
(1,810 |
) |
|
|
(4,837 |
) |
|
|
(3,697 |
) |
Preclinical programs |
|
|
(1,459 |
) |
|
|
(1,422 |
) |
|
|
(2,461 |
) |
|
|
(3,831 |
) |
Research and development personnel-related costs |
|
|
(7,617 |
) |
|
|
(15,368 |
) |
|
|
(19,943 |
) |
|
|
(26,243 |
) |
General and administrative expense |
|
|
(15,316 |
) |
|
|
(15,194 |
) |
|
|
(34,101 |
) |
|
|
(29,511 |
) |
Interest income, net |
|
|
1,814 |
|
|
|
5,271 |
|
|
|
4,888 |
|
|
|
11,636 |
|
Other segment items(1) |
|
|
(3,269 |
) |
|
|
(3,347 |
) |
|
|
(12,267 |
) |
|
|
(6,102 |
) |
Net loss |
|
$ |
(52,731 |
) |
|
$ |
(58,700 |
) |
|
$ |
(120,723 |
) |
|
$ |
(112,421 |
) |
(1) Includes other research and development costs, provision for income taxes, and other income (expense).
|